Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 13-valent pneumococcal conjugate vaccine with versus without polysorbate 80 in healthy infants
2006-001685-16Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine and Prevnar 13 in pneumococcal disease (2 arms), sponsored by Wyeth. Primary endpoint: Serotype-specific IgG response after infant series.
02
Drugs
pneumococcal 13-valent conjugate vaccinePrevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2006-001685-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001685-16.